VRCI.L

Verici Dx plc
Verici Dx PLC - Transfer of urine samples to Thermo Fisher
18th June 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 7733S
Verici Dx PLC
18 June 2024
 

Verici Dx plc

("Verici Dx" or the "Company") 

 

Transfer of urine samples to Thermo Fisher Scientific

Following completion of the transfer, full payment has been received

 

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces it has completed successful transfer of a portion of the Company's urine samples as announced as part of the global commercialisation and licensing agreement announced in November 20231. As previously stated, it demonstrates the additional value in the Company's data and sample assets for research.

 

Sara Barrington, CEO, said:

 

"We are delighted to announce the successful completion of this transfer, within the agreed timeline. This achievement not only highlights our commitment to delivering on our agreements, but also underscores the substantial value inherent in the Company's data and sample assets for research purposes."

 

Enquiries:

 

Verici Dx

www.vericidx.com

Sara Barrington, CEO 

investors@vericidx.com

Julian Baines, Chairman

 



 

 

Singer Capital Markets (Nominated Adviser & Broker)

Tel: +44 20 7496 3000

Aubrey Powell / Sam Butcher




  

 

Notes

1.     Please refer to RNS number 4652T for further information. A copy of this announcement can also be found on the company website https://verici-dx-plc.flint-platform.com/regulatory-news/44270

 

 

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.

 

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCQDLFFZQLEBBK]]>
TwitterFacebookLinkedIn